|
|
||||||||||||||
|
|
|||||||||||||||
PAPER |
1 Center for Movement Disorders Surgery, Columbia-Presbyterian Medical Center, Columbia University, New York, USA
2 Department of Neurology, Columbia-Presbyterian Medical Center
3 Center for Biostatistics and Epidemiology, Columbia-Presbyterian Medical Center
Correspondence to:
Correspondence to:
Dr B Ford
Neurological Institute, 710 West 168th Street, New York, New York 10032, USA; bford{at}neuro.columbia.edu
Objective: To measure the effect of deep brain stimulation (DBS) of the subthalamic nucleus in patients with advanced Parkinsons disease.
Design: Open label follow up using blinded ratings of videotaped neurological examinations.
Patients: 30 patients with advanced Parkinsons disease (19 male, 11 female; mean age 58.8 years; mean disease duration 12.8 years), complicated by intractable wearing off motor fluctuations and dopaminergic dyskinesias.
Main outcome measures: Unified Parkinsons disease rating scale (UPDRS), part III (motor), score at one year, from blinded reviews of videotaped neurological examinations. Secondary outcomes included the other UPDRS subscales, Hoehn and Yahr scale, activities of daily living (ADL) scale, mini-mental state examination (MMSE), estimates of motor fluctuations and dyskinesia severity, drug intake, and patient satisfaction questionnaire.
Results: Subthalamic nucleus stimulation was associated with a 29.5% reduction in motor scores at one year (p<0.0001). The only important predictors of improvement in UPDRS part III motor scores were the baseline response to dopaminergic drugs (p = 0.015) and the presence of tremor (p = 0.027). Hoehn and Yahr scores and ADL scores in the "on" and "off" states did not change, nor did the mean MMSE score. Weight gain occurred in the year after surgery, from (mean) 75.8 kg to 78.5 kg (p = 0.028). Duration of daily wearing off episodes was reduced by 69%. Dyskinesia severity was reduced by 60%. Drug requirements (in levodopa equivalents) declined by 30%.
Conclusions: The 30% improvement in UPDRS motor scores was a more modest result than previously reported. DBS did not improve functional capacity independent of drug use. Its chief benefits were reduction in wearing off duration and dyskinesia severity.
Abbreviations: ADL, activities of daily living; DBS, deep brain stimulation; MMSE, mini-mental state examination; STN, subthalamic nucleus; UPDRS, unified Parkinsons disease rating scale
Keywords: Parkinsons disease; deep brain stimulation; follow up
This article has been cited by other articles:
![]() |
V Fraix, J-L Houeto, C Lagrange, C Le Pen, P Krystkowiak, D Guehl, C Ardouin, M-L Welter, F Maurel, L Defebvre, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 443 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
R R Goodman, B Kim, S McClelland III, P B Senatus, L M Winfield, S L Pullman, Q Yu, B Ford, and G M McKhann II Operative techniques and morbidity with subthalamic nucleus deep brain stimulation in 100 consecutive patients with advanced Parkinson's disease J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 12 - 17. [Abstract] [Full Text] [PDF] |
||||
![]() |
W M M Schupbach, N Chastan, M L Welter, J L Houeto, V Mesnage, A M Bonnet, V Czernecki, D Maltete, A Hartmann, L Mallet, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1640 - 1644. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Rodriguez-Oroz, J. A. Obeso, A. E. Lang, J.-L. Houeto, P. Pollak, S. Rehncrona, J. Kulisevsky, A. Albanese, J. Volkmann, M. I. Hariz, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up Brain, October 1, 2005; 128(10): 2240 - 2249. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Capecci, R A Ricciuti, D Burini, V G Bombace, L Provinciali, M Iacoangeli, M Scerrati, and M G Ceravolo Functional improvement after subthalamic stimulation in Parkinson's disease: a non-equivalent controlled study with 12-24 month follow up J. Neurol. Neurosurg. Psychiatry, June 1, 2005; 76(6): 769 - 774. [Abstract] [Full Text] [PDF] |
||||
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |